Medtronic has received CE mark for its Percept RC neurostimulator for deep brain stimulation (DBS). The smallest and thinnest device on the market, Percept RC is the a rechargeable DBS system with BrainSense sensing technology.

Amaza Reitmeier, vice president and general manager for Medtronic Brain Modulation, said: “This development represents a critical step in our journey to transform Brain Modulation through sensing-enabled DBS. We are excited about the potential of Percept RC to provide a comfortable, personalised DBS therapy to those living with Parkinson’s Disease, Essential Tremor and Primary Dystonia. Percept RC is also the only rechargeable neurostimulator approved to serve patients with Epilepsy.”

Domenico De Paolis, vice president Neuromodulation International, which is part of the Neuroscience Portfolio at Medtronic, added: “In addition to being the smallest DBS device on the market, Percept RC combines proprietary battery technology with our brain-sensing technology. These innovations are the culmination of 30 years of investment in clinical trials and R&D to improve the experience of DBS patients.”

Overdrive battery technology allows physicians to adjust therapy without impacting battery capacity. With weekly charging, the device has greater than 99% battery capacity at 15 years. Rapid recharging means that patients can charge under normal conditions (from 10% to 90% full) in less than an hour.

The Percept family of devices also features Medtronic’s exclusive BrainSense technology, which enables physicians to track patient brain signals and correlate them with patient-recorded events, such as symptoms or side-effects associated with their disease, or the medications to treat it. Physicians can then tailor therapy to a patient’s evolving needs based on that information, rather than on clinical assessments and patient-reported data alone.

As well as proprietary battery technology, the Percept RC DBS system features several other innovative features:

Engineered for patient comfort, it’s the world’s smallest and thinnest dual-channel DBS device. Low-profile design allows for a deeper implant depth and minimal visibility of the device.

The Percept family is a DBS therapy with MR conditional labelling that allows for 3T and 1.5T full-body MRI scans (without having to turn off DBS therapy), providing patients access to medical imaging when they need it.

It’s designed to facilitate expanded capabilities, allowing the Percept RC devices of today to benefit from software updates of the future.

Percept RC is approved in the EU for the treatment of symptoms associated with Parkinson’s Disease (PD), Essential Tremor, Primary Dystonia, and Epilepsy.

The Percept RC neurostimulator will be available in Western Europe beginning mid-December and will launch in additional regions based on local regulations.

It is also available in Japan and under review by the U.S. Food and Drug Administration.